These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 25785753)
61. In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route. Ghosh A; Majie A; Karmakar V; Chatterjee K; Chakraborty S; Pandey M; Jain N; Roy Sarkar S; Nair AB; Gorain B AAPS PharmSciTech; 2024 May; 25(5):96. PubMed ID: 38710855 [TBL] [Abstract][Full Text] [Related]
62. Progress in brain targeting drug delivery system by nasal route. Khan AR; Liu M; Khan MW; Zhai G J Control Release; 2017 Dec; 268():364-389. PubMed ID: 28887135 [TBL] [Abstract][Full Text] [Related]
63. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair. Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949 [TBL] [Abstract][Full Text] [Related]
64. A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. Chen H; Chen CC; Acosta C; Wu SY; Sun T; Konofagou EE PLoS One; 2014; 9(10):e108880. PubMed ID: 25279463 [TBL] [Abstract][Full Text] [Related]
65. Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps. Kumar R; Gulati M; Singh SK; Sharma D; Porwal O CNS Neurol Disord Drug Targets; 2020; 19(9):663-675. PubMed ID: 32640969 [TBL] [Abstract][Full Text] [Related]
66. Nanoparticulate devices for brain drug delivery. Celia C; Cosco D; Paolino D; Fresta M Med Res Rev; 2011 Sep; 31(5):716-56. PubMed ID: 20162690 [TBL] [Abstract][Full Text] [Related]
67. Mechanism of intranasal drug delivery directly to the brain. Crowe TP; Greenlee MHW; Kanthasamy AG; Hsu WH Life Sci; 2018 Feb; 195():44-52. PubMed ID: 29277310 [TBL] [Abstract][Full Text] [Related]
68. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges. Kashyap K; Shukla R Curr Drug Deliv; 2019; 16(10):887-901. PubMed ID: 31660815 [TBL] [Abstract][Full Text] [Related]
69. [The role of MR and endoscopy in postoperative management of skull base reconstruction by vascular pedicle septal flap]. Zhang WT; Zhuang QX; Yin SK; Cheng FW; Guo J Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Feb; 26(4):152-6. PubMed ID: 22568252 [TBL] [Abstract][Full Text] [Related]
70. Access to the CNS: Strategies to overcome the BBB. Sánchez-Dengra B; González-Álvarez I; Bermejo M; González-Álvarez M Int J Pharm; 2023 Apr; 636():122759. PubMed ID: 36801479 [TBL] [Abstract][Full Text] [Related]
71. Minimally invasive nasal infusion (MINI) approach for CNS delivery of protein therapeutics: A case study with ovalbumin. Di Francesco V; Chua AJ; Davoudi E; Kim J; Bleier BS; Amiji MM J Control Release; 2024 Aug; 372():674-681. PubMed ID: 38909700 [TBL] [Abstract][Full Text] [Related]
72. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. League-Pascual JC; Lester-McCully CM; Shandilya S; Ronner L; Rodgers L; Cruz R; Peer CJ; Figg WD; Warren KE J Neurooncol; 2017 May; 132(3):401-407. PubMed ID: 28290002 [TBL] [Abstract][Full Text] [Related]
73. Mucocele rate after endoscopic skull base reconstruction using vascularized pedicled flaps. Bleier BS; Wang EW; Vandergrift WA; Schlosser RJ Am J Rhinol Allergy; 2011; 25(3):186-7. PubMed ID: 21679531 [TBL] [Abstract][Full Text] [Related]
74. Prospective transfrontal sheep model of skull-base reconstruction using vascularized mucosa. Mueller SK; Scangas G; Amiji MM; Bleier BS Int Forum Allergy Rhinol; 2018 May; 8(5):614-619. PubMed ID: 29227037 [TBL] [Abstract][Full Text] [Related]
75. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Gupta U; Kesharwani P; Ravichandiran V; Kumar P; Naidu VGM; Murty US; Ajazuddin ; Alexander A J Control Release; 2020 Nov; 327():235-265. PubMed ID: 32739524 [TBL] [Abstract][Full Text] [Related]
76. Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery. Kanazawa T; Fukuda M; Suzuki N; Suzuki T J Vis Exp; 2018 Nov; (141):. PubMed ID: 30507914 [TBL] [Abstract][Full Text] [Related]
77. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. Hanson LR; Frey WH BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S5. PubMed ID: 19091002 [TBL] [Abstract][Full Text] [Related]
78. Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Merkus FW; van den Berg MP Drugs R D; 2007; 8(3):133-44. PubMed ID: 17472409 [TBL] [Abstract][Full Text] [Related]
79. Beyond the nasoseptal flap: outcomes and pearls with secondary flaps in endoscopic endonasal skull base reconstruction. Patel MR; Taylor RJ; Hackman TG; Germanwala AV; Sasaki-Adams D; Ewend MG; Zanation AM Laryngoscope; 2014 Apr; 124(4):846-52. PubMed ID: 23877996 [TBL] [Abstract][Full Text] [Related]
80. Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling. Wang Q; Zhang Y; Wong CH; Edwin Chan HY; Zuo Z AAPS J; 2017 Dec; 20(1):23. PubMed ID: 29282567 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]